MasterCard Inc vs Medpace Holdings Inc — how do they compare? MasterCard Inc trades at $558.29 (market cap $491.83B), while Medpace Holdings Inc trades at $601.72 (market cap $16.90B). The key difference: MasterCard Inc is far larger — about 29.1× Medpace Holdings Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MA | MEDP | |
|---|---|---|
Market Cap | $491.83B | $16.90B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $598.96 | $620.59 |
52-Week Low | $471.55 | $393.42 |
Enterprise Value | $504.86B | $16.52B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $557.09, down 1.08% today, but maintains strong bullish technical momentum with consistent earnings beats and robust financial performance. The company reported Q2 2026 EPS of $5.04, beating expectations of $4.77, continuing a pattern of strong quarterly results. Revenue growth remains solid with 2025 revenue reaching $32.79 billion and net income of $14.97 billion, demonstrating the company's dominant position in payment processing. Recent institutional buying activity and positive analyst sentiment support the stock's upward trajectory.
Mastercard presents a compelling investment opportunity with strong fundamentals, consistent earnings growth, and bullish analyst consensus. The stock offers 18.6% upside to the consensus price target of $660.85. Key risks include competitive threats from emerging payment technologies and potential regulatory challenges in the financial services sector. The company's aggressive AI investments and global expansion initiatives position it well for continued growth, though investors should monitor payment industry disruption from stablecoins and digital payment innovations.
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →